Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Oh, Do‐Youn; Ruth He, Aiwu; Qin, Shukui; Chen, Li‐Tzong; Okusaka, Takuji; Vogel, Arndt; Won Kim, Jin; Suksombooncharoen, Thatthan; Ah Lee, Myung; Kitano, Masayuki; A. Burris, Howard; Bouattour, Mohamed; Tanasanvimon, Suebpong; G. McNamara, Mairéad; Zaucha, Renata; Avallone, Antonio; Tan, Benjamin; Cundom, Juan; Lee, Choong‐kun; Takahashi, Hidenori; Ikeda, Masafumi; Chen, Jen‐Shi; Wang, Julie; Makowsky, Mallory; Rokutanda, Nana; He, Philip; F. Kurland, John; Cohen, Gordon; W. Valle, Juan

doi:10.1056/evidoa2200015

Public

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Published in NEJM Evidence • Jun 1, 2022

Authors:

Do‐Youn Oh

Aiwu Ruth He

Shukui Qin

Abstract

BACKGROUND: Patients with advanced biliary tract cancer have a poor prognosis, and first-line standard of care (gemcitabine plus cisplatin) has remained unchanged for more than 10 years. The TOPAZ-1 trial evaluated durvalumab plus chemotherapy for patients with advanced biliary tract cancer. METHODS...

Subject

Durvalumab

Gemcitabine

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!